Recombinant Adeno-Associated Virus Serotype 9 Gene Therapy in Spinal Muscular Atrophy
Spinal muscular atrophy (SMA) is an autosomal recessive neuromuscular disease caused by deletion or mutation of the SMN1 gene. It is characterized by a progressive loss of motor neurons resulting in muscle weakness. The disease affects 1 in 11,000 live births and before the era of treatment SMA was...
Main Authors: | Katarzyna Kotulska, Aviva Fattal-Valevski, Jana Haberlova |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-10-01
|
Series: | Frontiers in Neurology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fneur.2021.726468/full |
Similar Items
-
New Treatments in Spinal Muscular Atrophy: Positive Results and New Challenges
by: Sonia Messina, et al.
Published: (2020-07-01) -
Experience and Perspectives in the US on the Evolving Treatment Landscape in Spinal Muscular Atrophy
by: Ramos-Platt L, et al.
Published: (2022-09-01) -
Treatment of spinal muscular atrophy with Onasemnogene Abeparvovec in Switzerland: a prospective observational case series study
by: Georg M. Stettner, et al.
Published: (2023-02-01) -
2020 Update to Spinal Muscular Atrophy Management in Saudi Arabia
by: Fahad A. Bashiri, et al.
Published: (2021-05-01) -
Social Media as a Source of Knowledge about Gene Therapy for Spinal Muscular Atrophy
by: Magdalena Tkaczuk, et al.
Published: (2022-12-01)